JAAD Pilot Pits Intralesional ALA-PDT Against Topical PDT With CO2 Laser

A randomized controlled pilot study set to appear in the November 2026 issue of JAAD directly compares single-session intralesional 5-aminolevulinic-acid photodynamic therapy against a topical ALA-PDT regimen combined with ablative carbon-dioxide laser in adults with refractory verruca vulgaris.

The trial, cataloged in Volume 95, Issue 5 of the Journal of the American Academy of Dermatology, randomizes patients with treatment-resistant common warts to either one intralesional ALA-PDT session or to topical ALA-PDT applied after CO2 laser ablation.

Investigators titled the work "Breaking the therapeutic depth barrier," framing the comparison as a test of whether photosensitizer delivery into the dermis can outperform surface-applied regimens in thick, hyperkeratotic lesions.

Yitao Qian leads the 14-author roster, with Wenjing Zha, Yiwu Yu, Szeman Cheung, Yibin Zeng, Fei Miao, Ting Lyu, Jie Shen, Ut Tong Chan, Jianhua Huang, and Li Xie among the named contributors. Hongwei Wang and Lei Shi anchor the senior investigator line.

The team's rationale rests on a depth-penetration limitation long associated with topical 5-ALA delivery through the stratum corneum of mature warts. The two tested strategies attack that barrier differently. One injects the prodrug directly into the lesion; the other ablates the surface before applying it.

What's the clinical context behind the comparison?

Refractory verruca vulgaris sits on a notoriously heterogeneous treatment menu. Salicylic acid, cryotherapy, intralesional Candida antigen, and pulsed-dye laser dominate the conventional rotation, with clearance rates that fall sharply in plantar, periungual, and multi-wart presentations.

PDT has lingered outside the standard algorithm partly because topical 5-ALA struggles to reach HPV-loaded keratinocytes buried in thick lesions. CO2 laser pretreatment has served as one workaround for years; direct intralesional injection is the alternative the new trial puts head-to-head against it.

What kind of evidence is a "pilot"?

The "pilot" tag signals small-sample, hypothesis-generating work. Investigators size pilot RCTs to estimate recruitment, protocol adherence, and variance — not to confirm efficacy.

Any cure-rate differential from this cohort will need a powered phase 2 or phase 3 follow-on. Standard pilot endpoints in PDT research typically include procedural pain on a visual analog scale, per-arm tolerability, and descriptive clearance at short follow-up.

Powered efficacy claims — complete clearance at 12 weeks with documented recurrence at six and twelve months — belong to a downstream trial, not the pilot itself. Materials currently cataloged from the journal do not list enrollment counts, complete-response rates, or follow-up windows, a gap that fits pilot-trial publication norms that defer granular outcomes to the full paper.

Dermatology Times expects the full text to surface those numbers when the November issue ships.

What's the forward-looking signal?

The phrase "therapeutic depth barrier" in the title telegraphs a mechanistic claim: depth of photosensitizer penetration, not raw ALA dose, limits topical PDT in verrucous disease.

Whether the pilot supports that leap, or simply flags feasibility for a future definitive trial, is the question that will shape how practicing dermatologists read this paper. Watch for the full reported cure rate, time-to-clearance, pain scores, and recurrence curves at the standard 3-, 6-, and 12-month checkpoints.